ANRO Collar Strategy
ANRO (Alto Neuroscience, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NYSE.
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects.
ANRO (Alto Neuroscience, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $948.9M, a beta of 1.25 versus the broader market, a 52-week range of 2.15-28.441, average daily share volume of 343K, a public-listing history dating back to 2024, approximately 76 full-time employees. These structural characteristics shape how ANRO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.25 places ANRO roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a collar on ANRO?
A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.
Current ANRO snapshot
As of June 30, 2026, spot at $26.30, ATM IV 128.40%, IV rank 22.17%, expected move 36.81%. The collar on ANRO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this collar structure on ANRO specifically: IV regime affects collar pricing on both sides; compressed ANRO IV at 128.40% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 36.81% (roughly $9.68 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ANRO expiries trade a higher absolute premium for lower per-day decay. Position sizing on ANRO should anchor to the underlying notional of $26.30 per share and to the trader's directional view on ANRO stock.
ANRO collar setup
The ANRO collar below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ANRO near $26.30, the first option leg uses a $27.62 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ANRO chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ANRO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $26.30 | long |
| Sell 1 | Call | $27.62 | N/A |
| Buy 1 | Put | $24.99 | N/A |
ANRO collar risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.
ANRO collar payoff curve
Modeled P&L at expiration across a range of underlying prices for the collar on ANRO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use collar on ANRO
Collars on ANRO hedge an existing long ANRO stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
ANRO thesis for this collar
The market-implied 1-standard-deviation range for ANRO extends from approximately $16.62 on the downside to $35.98 on the upside. A ANRO collar hedges an existing long ANRO position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current ANRO IV rank near 22.17% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ANRO at 128.40%. As a Healthcare name, ANRO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ANRO-specific events.
ANRO collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ANRO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ANRO alongside the broader basket even when ANRO-specific fundamentals are unchanged. Always rebuild the position from current ANRO chain quotes before placing a trade.
Frequently asked questions
- What is a collar on ANRO?
- A collar on ANRO is the collar strategy applied to ANRO (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With ANRO stock trading near $26.30, the strikes shown on this page are snapped to the nearest listed ANRO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ANRO collar max profit and max loss calculated?
- Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the ANRO collar priced from the end-of-day chain at a 30-day expiry (ATM IV 128.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ANRO collar?
- The breakeven for the ANRO collar priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ANRO market-implied 1-standard-deviation expected move is approximately 36.81%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a collar on ANRO?
- Collars on ANRO hedge an existing long ANRO stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
- How does current ANRO implied volatility affect this collar?
- ANRO ATM IV is at 128.40% with IV rank near 22.17%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.